| Literature DB >> 31340322 |
Glaucia Luciano da Veiga1, Raissa Daniel Machado da Silva2, Edimar Cristiano Pereira2, Ligia Ajaime Azzalis2, Beatriz da Costa Aguiar Alves1, Flavia de Sousa Gehrke1,3, Thaís Moura Gascón1, Fernando Luiz Affonso Fonseca1,2.
Abstract
Breast cancer (BC) is one of the primary health problems worldwide. As the most common cancer in women in the world and in Brasil, behind only non-melanoma skin cancer, this neoplasm corresponds to approximately 28% of new cases per year in the country. BC also affects men, although the incidence corresponds to only 1% of total cases. Currently, most of the chemotherapeutic agents used in BC treatment are extremely toxic and cause long-term side effects. There is also a need to obtain earlier diagnoses, more accurate prognoses and make new therapies available that are more selective and effective in order to improve the current scenario. Therefore, this work sought to evaluate the importance of the biomarker survivin (Sur) in relation to BC, through the detailing of the role of Sur as a biomarker, the correlation between this protein and the prognosis of BC patients, and a summary of therapeutic strategies that target Sur for the development of new anticancer therapies.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31340322 DOI： 10.1590/1806-9282.65.6.893
Source DB: PubMed Journal: Rev Assoc Med Bras (1992) ISSN： 0104-4230 Impact factor: 1.209